Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 3,236 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Heart Failure, Diabetes Mellitus
Interventions: Libre 2 rt-CGM, POC BG + Blinded CGM; Device · Diagnostic Test
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Infertility, Female, Infertility, Male
Interventions: Spent media collection; Other
Lead sponsor: Genomic Prediction Inc.; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: North Brunswick, New Jersey

Conditions: Hearing Loss
Interventions: Hearing instrument; Device
Lead sponsor: Sonova AG; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Aurora, Illinois

Conditions: Multiple Sclerosis, Multiple Sclerosis (MS)
Interventions: My MS Toolkit; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
Interventions: Empagliflozin 10 MG, Placebo Oral Tablet; Drug
Lead sponsor: Justin Ryder; Other
Eligibility: 12 Years to 20 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Achalasia, Esophageal, GERD (Gastroesophageal Reflux Disease)
Interventions: Conventional POEM, Sling Fiber-Preserving POEM; Procedure
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Orange, California

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Biospecimen Collection, Oral nicotine pouches, Survey Administration; Procedure · Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pregnancy, Preconception Education, Preconception Care, Preconception Risk, Adverse Pregnancy Outcomes
Interventions: Healthy lifestyle education; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Skin Graft Donor Site, Wound Healing, Split-Thickness Skin Graft
Interventions: RECELL® Autologous Cell Harvesting Device, Standard Transparent Film Dressing; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Airway Disorder
Interventions: High flow, Low Flow; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 0 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Lutetium Lu 177 Vipivotide Tetraxetan, PSMA PET Scan, Questionnaire Administration, Single Photon Emission Computed Tomography; Procedure · Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Ulcerative Colitis
Interventions: CurQD, Placebo, Vedolizumab; Drug
Lead sponsor: Ryan C Ungaro; Other
Eligibility: 18 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: New York, New York

Conditions: Anterior Cruciate Ligament (ACL) Reconstruction
Interventions: Mind in Motion; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 15 Years to 30 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
Interventions: Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 2
States / cities: Birmingham, Alabama • St Louis, Missouri

Conditions: Asthma in Children, Asthma Chronic
Interventions: Asthma Ctrl+, Control; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years to 18 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Aurora, Colorado • Cincinnati, Ohio

Conditions: Amplified Musculoskeletal Pain Syndrome (AMPS)
Interventions: Nerivio(R) Device, Usual Care; Device · Other
Lead sponsor: Children's Health; Other
Eligibility: 8 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prediabetes or Overweight
Interventions: Whole food fiber mixture, inulin; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Social Cognition, Personality Disorder, Mental Health, Interpersonal Conflict
Interventions: Social Learning Task Battery, Clinical Cohort, Social Learning Task Battery, Online Cohort; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1,612 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer Risk, Cardiovascular Disease Risk, Cardiometabolic Risk, Diabetes
Interventions: Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up; Behavioral
Lead sponsor: Precision Health Equity Initiative; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2035
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Vaping
Interventions: Exposure to Influencer Age and Context Variations in E-Cigarette Marketing; Other
Lead sponsor: University of Southern California; Other
Eligibility: 14 Years to 17 Years
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Interventions: Low-Dose Naltrexone, 1.5mg, Low-Dose Naltrexone, 3.0mg, Low-Dose Naltrexone, 4.5mg, Low-Dose Naltrexone, 6.0mg; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Participants With Advanced Solid Tumor Malignancies
Interventions: VBC106; Drug
Lead sponsor: VelaVigo Bio Inc; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Houston, Texas • West Valley City, Utah • Fairfax, Virginia

Conditions: Inflammation, Gastrointestinal Symptoms
Interventions: Multi-Strain Postbiotic, Placebo; Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: GVHD - Graft-Versus-Host Disease
Interventions: Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: New Hyde Park, New York

Search by objective public record fields.

CGM Use in Heart Failure

Cell Free Preimplantation Genetic Testing

Evaluation of Investigational Hearing Instrument Features

My MS Toolkit: An Internet-Based Depression Self-Management Program for Adults Living With Multiple Sclerosis

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

Sling-Fiber Preservation POEM vs. Conventional POEM for Reducing Post-POEM GERD

Studying Different Ways of Using Oral Nicotine Pouches to Understand the Effect on Nicotine Delivery, Appeal, and Side Effects Among Adult Cigarette Smokers

Lifestyle, Education, Activity, Nutrition (LEAN) Into Pregnancy

Autologous Skin Cell Suspension (RECELL®) for Accelerated Healing of Split-Thickness Skin Graft Donor Sites: A Randomized, Intra-Patient (Split-Site) Controlled Trial

Optimizing High Flow Nasal Cannula Oxygenation in Pediatric Airway Procedures

Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer

Combination CurQD and Vedolizumab in Ulcerative Colitis

Feasibility of a Mindfulness and Physical Activity Promotion Intervention After Anterior Cruciate Ligament Reconstruction

Semaglutide for Low Back Pain

Asthma Ctrl SMART Trial

Efficacy and Safety of Nerivio for the Management of Amplified Musculoskeletal Pain Syndrome in Pediatric Patients

Whole Food Fibers for Support of Key Gut Bacteria for Human Health

Neurocomputational Dynamics of Cooperation

The RISC Registry--Risk Informed Screening Registry

E-cigarette Social Media Marketing and Its Perceptions by Youth

Low-Dose Naltrexone For ME/CFS: Dose-Finding

First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors

Evaluating the Ability of a Multi-Strain Postbiotic to Impact Inflammation, Immune Components, Gastrointestinal Symptoms, Recovery, Anxiety, and Intestinal Permeability

Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT